Kodiak Sciences Inc
KOD7.310USD
+0.660+9.92%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
385.62MValor de mercado
PerdaP/L TTM
Mais detalhes de Kodiak Sciences Inc Empresa
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Informações da empresa
Código da empresaKOD
Nome da EmpresaKodiak Sciences Inc
Data de listagemOct 04, 2018
CEODr. Victor Perlroth, M.D.
Número de funcionários109
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço1250 Page Mill Road
CidadePALO ALTO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94304
Telefone16502810850
Sitehttps://kodiak.com/
Código da empresaKOD
Data de listagemOct 04, 2018
CEODr. Victor Perlroth, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
Tipos de investidores
Investidores
Proporção
Hedge Fund
46.97%
Investment Advisor
18.19%
Investment Advisor/Hedge Fund
13.56%
Individual Investor
5.53%
Research Firm
1.50%
Endowment Fund
1.31%
Pension Fund
0.18%
Venture Capital
0.09%
Bank and Trust
0.07%
Other
12.61%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
273
46.04M
87.25%
-8.22M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
2023Q1
414
44.84M
85.66%
-7.92M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
17.31M
32.81%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.37%
-21.30K
-0.75%
Mar 31, 2025
Perlroth (Victor D)
2.70M
5.11%
+527.00K
+24.31%
Mar 31, 2025
Acadian Asset Management LLC
1.95M
3.69%
+413.82K
+27.01%
Mar 31, 2025
The Vanguard Group, Inc.
1.69M
3.2%
+6.61K
+0.39%
Mar 31, 2025
Adage Capital Management, L.P.
1.33M
2.51%
+186.18K
+16.34%
Mar 31, 2025
ICONIQ Capital, LLC
1.27M
2.4%
+249.70K
+24.56%
Mar 31, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.07M
2.03%
+548.67K
+104.76%
Mar 31, 2025
Boxer Capital Management, LLC
1.03M
1.96%
+35.00K
+3.50%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
ProShares UltraPro Russell2000
0%
Vanguard US Momentum Factor ETF
0%
Ver Mais
Fidelity Enhanced Small Cap ETF
Proporção0.04%
iShares Micro-Cap ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
Schwab U.S. Small-Cap ETF
Proporção0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Vanguard US Momentum Factor ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
